NDAORALTABLETPriority Review
Approved
Feb 2025
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
4/8 — Partial
Priority Review
CTEXLI (chenodiol) by Mirum Pharmaceuticals is (chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. Approved for cerebrotendinous xanthomatosis (ctx) in adults. First approved in 2025.
Drug data last refreshed 19h ago
Mechanism of Action
(chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. In CTX, the major bile acid synthesis pathways are disrupted due to partial or total deficiency in sterol 27-hydroxylase encoded by the CYP27A1 gene. CTEXLI may act to replace deficient levels of the…
Pharmacologic Class:
Bile Acid
Indications (1)
Worked on CTEXLI at Mirum Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.